Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET study of individualized fludarabine dosing in allogeneic stem cell transplantation
NL-OMON55832Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fludarabine in hematopoietic malignancies, leukemia, lymphoma and 2 more (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Cumulative incidence of severe viral infections at day 100. Started Mar 2019; status: completed.
02
Drugs
fludarabine
03
Conditions
hematopoietic malignanciesleukemialymphomamyelodysplastic syndrome (MDS)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on NL-OMON55832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55832.